A once-daily pill combined with chemotherapy left pancreatic tumours undetectable on scans in about one in 12 patients with advanced disease, an early clinical trial has found. The result represents a complete response to treatment, rather than proof of a cure.
The phase-one/two study of daraxonrasib involved 61 patients, with a median follow-up of 18 months. Tumours shrank or disappeared in 60.7%, including complete responses in 8.2%. The disease control rate, encompassing tumours that shrank, disappeared or stopped growing, was 90.2%.
After one year, 76.6% of patients were alive, compared with around 40% to 45% with chemotherapy alone. That comparison is encouraging, but the small, initial study does not settle how much benefit the combination delivers. Across the group, the reported average time before tumours returned or began growing again was 12.8 months.
Daraxonrasib targets growth signalling associated with mutated KRAS, found in more than nine in 10 pancreatic tumours. Findings reported in May suggested the drug almost doubled survival time compared with chemotherapy alone and caused fewer side effects. In the new study, fewer than 5% discontinued treatment.
Dr Wungki Park, an oncologist at Memorial Sloan Kettering Cancer Centre in New York, presented the findings at the European Organisation for Research and Treatment of Cancer in Barcelona. He called them ‘a massive, massive breakthrough’.
Asked whether patients whose tumours were no longer visible were cured, he said: ‘This is the closest to cure.’ However, he said longer-term survival data would follow and acknowledged that cancer frequently develops resistance to treatment; the combination aims to delay that resistance.
Dr Madina Kara, head of research at Pancreatic Cancer UK, welcomed the evidence that the treatments could work together while stressing the study’s small size. Half of people with pancreatic cancer die within three months of diagnosis, she said. She called for greater UK investment in research and trials, alongside rapid access to treatments once proven effective.
More than 11,000 people are diagnosed with pancreatic cancer annually in the UK and more than 10,000 die from it, usually within months.
Cancer Research UK chief executive Michelle Mitchell described the findings as the biggest advance in decades, but said more trials were needed before NHS assessment and further research should examine combinations with other therapies.
The phase-three study has recruited enough patients in the US, though some European sites may still have places. Its results and longer follow-up will help establish whether these scan responses translate into lasting survival gains.









Join the conversation